The regulation and importance of monocyte chemoattractant protein-1

被引：249

作者：

Bianconi, Vanessa ^{[1
]}

Sahebkar, Amirhossein ^{[2
]}

Atkin, Stephen L. ^{[3
]}

Pirro, Matteo ^{[1
]}

机构：

[1] Univ Perugia, Hosp Santa Maria Misericordia, Unit Internal Med, Dept Med, Perugia, Italy

[2] Mashhad Univ Med Sci, Biotechnol Res Ctr, Mashhad, Iran

[3] Weill Cornell Med Qatar, Doha, Qatar

来源：

CURRENT OPINION IN HEMATOLOGY | 2018年 / 25卷 / 01期

关键词：

atherosclerosis; cancer; CC chemokine receptor 2; inflammation; monocyte chemoattractant protein; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CHEMOKINE RECEPTOR; MACROPHAGE INFILTRATION; METABOLIC SYNDROME; PANCREATIC-CANCER; MCP-1; CHEMOKINE; CURCUMIN; EXPRESSION; TUMOR; CCR2;

D O I：

10.1097/MOH.0000000000000389

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Purpose of review Monocyte chemoattractant protein (MCP)-1, a chemokine regulating monocyte chemotaxis and T-lymphocyte differentiation by binding to the CC chemokine receptor 2 (CCR2), plays a crucial role in the pathogenesis of inflammatory diseases, atherosclerosis and cancer. This review summarizes the current knowledge on the regulation and importance of the MCP-1/CCR2 axis, focusing on the therapeutic potential of its inhibition. Recent findings Differential modulation of MCP-1 and CCR2 lead to downstream activation pathways, pathogenetic to differing disease conditions characterized by dysregulated monocyte/macrophage tissue recruitment. Pharmacological targeting of the MCP-1/CCR2 axis has led to selective MCP-1/CCR2 antagonists that have now entered phase I/II clinical trials for the treatment of inflammatory diseases, atherosclerosis and cancer. The pleiotropic nonselective MCP-1/CCR2 inhibition by current pharmacological agents is thought to contribute to their anti-inflammatory and antiatherosclerotic effects that is also seen for nutraceutical compounds such as curcumin. Summary MCP-1 has a critical role in regulating chemotaxis both in health and disease, with increasing interest in its pharmacological inhibition. However, the therapeutic efficacy and safety of targeting the MCP-1/CCR2 axis is still in evolution.

引用

页码：44 / 51

页数：8

共 86 条

[1]

Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: A nature-made jack-of-all-trades? [J].

Abdollahi, Elham ;

Momtazi, Amir Abbas ;

Johnston, Thomas P. ;

Sahebkar, Amirhossein .

JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (02) :830-848

[2]

Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice [J].

Aiello, RJ ;

Bourassa, PAK ;

Lindsey, S ;

Weng, WF ;

Natoli, E ;

Rollins, BJ ;

Milos, PM .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (06) :1518-1525

[3]

CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE-/- mice [J].

Aiello, Robert J. ;

Perry, Bret D. ;

Bourassa, Patricia-Ann ;

Robertson, Andrew ;

Weng, Weifan ;

Knight, Delvin R. ;

Smith, Andrew H. ;

Frederick, Kosea S. ;

Kalgutkar, Amit ;

Gladue, Ronald P. .

ATHEROSCLEROSIS, 2010, 208 (02) :370-375

[4]

Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells [J].

An, Jun ;

Xue, Ying ;

Long, Meijun ;

Zhang, Ge ;

Zhang, Junhang ;

Su, Hang .

ONCOTARGET, 2017, 8 (24) :39230-39240

[5]

[Anonymous], 2015, MATH PROBL ENG

[6]

International Union of Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors [J].

Bachelerie, Francoise ;

Ben-Baruch, Adit ;

Burkhardt, Amanda M. ;

Combadiere, Christophe ;

Farber, Joshua M. ;

Graham, Gerard J. ;

Horuk, Richard ;

Sparre-Ulrich, Alexander Hovard ;

Locati, Massimo ;

Luster, Andrew D. ;

Mantovani, Alberto ;

Matsushima, Kouji ;

Murphy, Philip M. ;

Nibbs, Robert ;

Nomiyama, Hisayuki ;

Power, Christine A. ;

Proudfoot, Amanda E. I. ;

Rosenkilde, Mette M. ;

Rot, Antal ;

Sozzani, Silvano ;

Thelen, Marcus ;

Yoshie, Osamu ;

Zlotnik, Albert .

PHARMACOLOGICAL REVIEWS, 2014, 66 (01) :1-79

[7]

Examination of genetic effects of polymorphisms in the MCP-1 and CCR2 genes on MI in the Icelandic population [J].

Bjarnadottir, Kristjana ;

Eiriksdottir, Gudny ;

Aspelund, Thor ;

Gudnason, Vilmundur .

ATHEROSCLEROSIS, 2006, 188 (02) :341-346

[8]

Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis [J].

Boring, L ;

Gosling, J ;

Cleary, M ;

Charo, IF .

NATURE, 1998, 394 (6696) :894-897

[9]

A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy [J].

Bot, Ilze ;

Zacarias, Natalia V. Ortiz ;

de Witte, Wilhelmus E. A. ;

de Vries, Henk ;

van Santbrink, Peter J. ;

van der Velden, Daniel ;

Kroner, Mara J. ;

van der Berg, Dirk-Jan ;

Stamos, Dean ;

de Lange, Elizabeth C. M. ;

Kuiper, Johan ;

IJzerman, Adriaan P. ;

Heitman, Laura H. .

SCIENTIFIC REPORTS, 2017, 7

[10]

Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells [J].

Brown, Christine E. ;

Vishwanath, Reena P. ;

Aguilar, Brenda ;

Starr, Renate ;

Najbauer, Joseph ;

Aboody, Karen S. ;

Jensen, Michael C. .

JOURNAL OF IMMUNOLOGY, 2007, 179 (05) :3332-3341

← 1 2 3 4 5 6 7 8 9 →